Xiamen, a professor at the university of developing new drugs to the treatment of locally advanced colorectal cancer (http://www.chemdrug.com/), which has obtained the FDA (http://www.chemdrug.com/article/11/) (the United States food and drug administration (http://www.chemdrug.com/)) permission, can enter the human trials (http://www.chemdrug.com/sell/24/), the clinical trials will be conducted by the United States an institute of harvard medical school. 

 

Xiamen university has released the news that xiamen university professor xiao-kun zhang, dean of college of leadership team original cancer drug research and development, has been approved by the FDA for clinical trial license, officially entered the new drug clinical trials before being approved of stage, to carry out clinical trials in patients with advanced colorectal cancer. Look from the animal experiments, a new drug has effect on gastric cancer, breast cancer. 

 

New cancer drug - the original K - 80003 (TX - 803) is the result of xiao-kun zhang professor at xiamen university in 2010 to make important academic found that it is a targeted high expression of cancer of the colon cancer such as protein tRXR alpha type high-efficiency, targeted cancer drugs, can effectively inhibit cancer cell survival and lead to apoptosis. Researchers in tumor tissues in patients with colorectal cancer, gastric cancer and breast cancer in clinical samples tested (http://www.chemdrug.com/sell/76/) found that when they tumor tissue contains a lot of tRXR alpha oncoprotein, that is to say, this kind of patient enough of K - 80003 working object of the action of drugs (http://www.chemdrug.com/), drug therapy effect will be very significant. 

 

According to xiamen university aspect, from theory research to the original disease found unique new drug targets, and finally develop high-efficiency, new drug molecule structure, K - 80003 without grafting, no fake, is a real sense of the word, with independent intellectual property rights of innovative drugs.